ReviewArthritis research & therapy2009
Developments in the clinical understanding of lupus.
Review in Arthritis research & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 48 citations in OpenAlex.
- Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience.Cell transplantation · 2013Trial
- Dysregulated Intestinal Host-Microbe Interactions in Systemic Lupus Erythematosus: Insights from Patients and Mouse Models.Microorganisms · 2025Review
- A Study of IFN-α-Induced Chemokines CCL2, CXCL10 and CCL19 in Patients with Systemic Lupus Erythematosu.Life (Basel, Switzerland) · 2022Article
- IL233, an IL-2-IL-33 hybrid cytokine induces prolonged remission of mouse lupus nephritis by targeting Treg cells as a single therapeutic agent.Journal of autoimmunity · 2019Article
- Regulatory T cells in acute and chronic kidney diseases.American journal of physiology. Renal physiology · 2018Review
- Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence.Stem cells international · 2016Review
- Type I interferon in the pathogenesis of lupus.Journal of immunology (Baltimore, Md. : 1950) · 2014Review
- Nucleic Acid sensors and type I interferon production in systemic lupus erythematosus.Frontiers in immunology · 2013Review
- Excess female siblings and male fetal loss in families with systemic lupus erythematosus.The Journal of rheumatology · 2013Article
- Hematopoietic stem cell transplantation for systemic lupus erythematosus.Clinical & developmental immunology · 2012Review
- Role of cytokines in systemic lupus erythematosus: recent progress from GWAS and sequencing.Journal of biomedicine & biotechnology · 2012Review
- Association study of ITGAM, ITGAX, and CD58 autoimmune risk loci in systemic sclerosis: results from 2 large European Caucasian cohorts.The Journal of rheumatology · 2011Article
- A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients.EMBO molecular medicine · 2011Article
- Interferon-alpha: a therapeutic target in systemic lupus erythematosus.Rheumatic diseases clinics of North America · 2010Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in genetics and new understanding of the molecular pathways that mediate innate and adaptive immune system activation, along with renewed focus on the role of the complement system as a mediator of inflammation, have stimulated elaboration of a scheme that might explain key mechanisms in the pathogenesis of systemic lupus erythematosus. Clinical observations identifying important comorbidities in patients with lupus have been a recent focus of research linking immune mechanisms with clinical manifestations of disease. While these advances have identified rational and promising targets for therapy, so far the therapeutic trials of new biologic agents have not met their potential. Nonetheless, progress in understanding the underlying immunopathogenesis of lupus and its impact on clinical disease has accelerated the pace of clinical research to improve the outcomes of patients with systemic lupus erythematosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.